JNJ-78934804 not checked
Johnson & Johnson (Janssen) · JNJ-4804
FollowEvery change as it happens, and a Monday email
Trials
4 active
4 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “JNJ-78934804 will be administered subcutaneously as per defined regimen.”In the company’s words, NCT05242484 on ClinicalTrials.gov
- Tested for
- Colitis, Ulcerative (2 trials), Crohn Disease, Crohn's Disease
- Main trialPhase 3
- “The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).”In the company’s words, NCT07577843 on ClinicalTrials.gov
- Other names
- JNJ-4804
Other drugs for Colitis, Ulcerative
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up2
- 12 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 11 Aug 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 12 Jun 2028 | A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Recruiting | 11 Aug 2028 | A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Active, not recruiting | 15 May 2025 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Active, not recruiting | 23 May 2025 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026